Drug intelligence / Profile preview

PNV-021

Development stage: Unknown
Lead developer: Fred Hutchinson Cancer Center
Modality: Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics

Overview

PNV-021 is a personalized neoantigen peptide vaccine developed to treat melanoma that is refractory to PD-1 inhibitors. This vaccine is designed to induce tumor-specific T-cell responses by presenting up to 20 predicted HLA class I/II binding neoantigen peptides to the immune system. In a phase I study, PNV-021 was administered alongside Poly-ICLC and nivolumab, demonstrating strong immune activation, increased immune-cell infiltration within tumors, and the expansion of neoantigen-reactive T cells in peripheral blood.

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on PNV-021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNV-021.

Explore the full profile